Sl. No.	Name of the Company	Name of the product
1	M/s Sarabhai M Chemicals	Vitamin C
2	M/s Warner Hindustan	Isokin
3	M/s Boehringer Knoll Ltd.	Englucon
4	M/s IDPL	Imported bulk drug
5	M/s A.P. Chemicals	Paracetamol
6	M/s Malladi drugs	Ephedrine
7	M/s Krupa Traders	Rifampicin
8	M/s IDPL	Sulphadimidine
9	M/s Sandoz (I) Ltd.	Multi vitamin
10	M/s Pfizer (I) Ltd.	Do.
11	M/s Lupin Labs.	Rifampicin and Ethambutol Combiflame
12	Crews Pharmaceuticals	Combiflame

Examination of compl ints received against the drug compaanies on the issues of overch arging and related matter is an ongoing process and all these cases are at various stages of examination.

References to the collectors for recovery of amounts due under DPEA

404. CHOWDHARY RAM SEWAK: Will the PRIME MINISTER be pleased to state:

(a) what are the details of references made to the collectors for recovery of amounts due under DPEA as arrears of land revenue after the Supreme Court Judgement on the drug prices litigation;

(b) whether it is a fact that Government have withdrawn certain references;

(c) if so, what are the details thereof and on what basis these references were withdrawn; and

(d) what steps have been taken to refer the matter to collectors for recovery in cases where amounts have been communicated to drug companies up to 30th June, 1991?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) In February, 1988, Department had requested the Deputy Commissioner, Delhi to issue necessary certificates under section 3 of Revenue Recovery Act 1990, to Collector of Bombay for affecting recovery of the amounts due from some of the Drug Companies for deposit in the DPEA. Subsequently, however it was decided, in April 1988, to stay proceedings against any company who had made part payment. The recovery certificates were, therefore, returned by the collectors in those cases.

(d) The question of recovering the amount as arrears of land revenue by referring the matter to collector concerned will be considered.

Prices of Flucort range of formulations

405. CHOWDHARY RAM SEWAK: Will the PRIME MINISTER be pleased to refer answer to Unstarred Question 219 given in Raya Sabha on

the 25th February, 1991 and state when the prices of Flucort range of formulations were reduced and since when the reduced prices were implemented and what is the estimated amount overcharged from consumers in the interim period?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): The reduced prices of Flucort range of formulations were fixed on 9-3-1990. From the information/ details made available to the Government by the manufacturer of Flucort range of formulations, the company had implemented the reduced prices in July, 1990 According to the company, they did not manufacture any batch of these formulations during April and May, 1990. The quantum of overcharged amount will be worked out after calling complete details of production, sales etc. from the company.

Challenging the actions taken under DPEA

406 SHRI MOHD. KHALEELUR RAHMAN: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that certain drug companies have gone to various High Courts challenging the action taken by Government against overcharging of prices and recoveries of liabilities under DPEA;

(b) if so, names of the companies and names of High Courts whether writ petitions have been filed;

(c) what is the present position in each case;

(d) what are the details of instances of overcharging of prices came into the notice of his Ministry and what action was taken in each case; and

(e) what are the details of claim notices sent by his Ministry upto 30th June, 1991 and what is the response in each case?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Yes, Sir.

(b) and (c) The information will be compiled and laid on the Table of the House, as soon as possible.

(d) and (e) The names of the companies and products involved are given below:—

Sl. No.	Name of the Company	Name of the Product
(i)	M/s Sarabhai M. Chemicals	Vitamin C
(ii)	M/s Warner Hindustan	Isokin
(iii)	M/s Boehringer Knoll Ltd.	Euglucion
(iv)	M/s IDPL	Imported bulk drug
(v)	M/s A.P. Chemicals	Paracetamol
(vi)	M/s Malladi drugs	Ephedrine
(vii)	M/s IDPL	Sulphadimidine
(viii)	M/s Krupa Traders	Rifampicin
(xi)	M/s Sandoz (I) Ltd.	Multi vitamin
(x)	M/s Pfizer (I) Ltd.	Do.
(xi)	M/s Lupin Labs	Rifampicin & Ethambutol
(xii)	M/s Carew Pharmaceuticals	Combiflame

Examination of complaints received against the drug companies on the issues of overcharging and related matter is an on-going process and these cases are at various stages of examination.